By Salvatore La Rosa, VP Research and Development
Early investments from the Children’s Tumor Foundation are paying off and delivering innovative and impactful research. It’s great to see research moving forward thanks to the support of both private and public funding. Our philosophy of betting on high-risk high-reward projects is proving successful and will eventually help us realize our vision of ending NF.
Lai Man (Natalie) Wu, PhD, of Cincinnati Children’s Hospital Medical Center, is first author on a recently published article in Cancer Cell. This study, funded in part by a 2017 Young Investigator Award from the Children’s Tumor Foundation, suggests ways to attack MPNSTs.
Research funded by the Children’s Tumor Foundation (CTF) and led by Ludwine Messiaen, PhD, professor of genetics at the University of Alabama at Birmingham (UAB), has shown that missense mutations in a cluster of just five codons in the NF1 gene are an important risk factor for severe symptoms of the genetic disorder neurofibromatosis (NF) type 1, thereby improving the predictability of this condition when these specific mutations are present in an individual. This work was published today in the American Journal of Human Genetics.
An article about the Children’s Tumor Foundation-funded International Schwannomotosis Database that was published in a recent issue of American Journal of Medical Genetics was just added to the PubMed US National Library of Medicine, a database hosted by the National Institutes of Health that houses more than 27 million citations for biomedical literature.
Early research funded by the Children's Tumor Foundation has led to developments in schwannomatosis research. One award (2008) was for the development of the first mouse model for schwannomatosis with the same underlying gene mutations found in schwannomatosis patients. The second award (2011) was to support their use in a screening platform for schwannomatosis therapeutic agents.